EIM
ADMS

Essex Investment Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Essex Investment Management’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-278,011
Closed -$1.2M – 526
2020
Q4 		$1.2M Sell
278,011
-51,426
-16% -$220K 0.15% 211
2020
Q3 		$1.36M Buy
+329,437
New +$1.27M 0.19% 173

Other funds holding ADMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CCPM
Cooper Creek Partners Management New York $2.92B AUM 30.49% 1-Year Est. Return

Essex Investment Management's ADMS Position: Q1 2021 in Review

Essex Investment Management sold out of Adamas Pharmaceuticals (ADMS) in Q1 2021, closing a stake of 278,011 shares — an estimated $1.2M sold.

Essex Investment Management first reported a position in ADMS in Q3 2020 and held it in 2 quarters. The position peaked at $1.36M in Q3 2020. 73 funds tracked by Wall St. Rank hold ADMS as of Q1 2021.

  • Essex Investment Management reported no remaining Adamas Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Essex Investment Management sold 278,011 Adamas Pharmaceuticals shares in Q1 2021, an estimated $1.2M.
  • Essex Investment Management first reported a position in Adamas Pharmaceuticals in Q3 2020 and held it in 2 quarters.
  • Essex Investment Management's Adamas Pharmaceuticals position peaked at $1.36M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2021.

Based on Essex Investment Management's 13F filing for Q1 2021, filed 12 May 2021.